All In Biotech

Investigational drug · Phase 3

DR10624

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Severe Hypertriglyceridemia, Hypertriglyceridemia, Severe Hypertriglyceridemia (sHTG).

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

4 still active

All registered trials

7

Any phase or sponsor naming "DR10624"

First trial start

2024

Aug 1, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "DR10624", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Severe Hypertriglyceridemia
  • Hypertriglyceridemia
  • Severe Hypertriglyceridemia (sHTG)
  • MASLD

Approved drugs for the same conditions: High triglycerides · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "DR10624" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Severe Hypertriglyceridemia

  • PegozaferminBIO89-100Phase 33 trials

    Roche (Genentech) · Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Severe Hypertriglyceridemia

  • ION775Phase 21 trial

    Ionis Pharmaceuticals · Hypertriglyceridemia, Severe Hypertriglyceridemia

  • SolbinsiranLY3561774Phase 21 trial

    Eli Lilly · Severe Hypertriglyceridemia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.